Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0099-5428(03)30008-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and Validation of a Test to Identify Drugs That Cause Idiosyncratic Drug-Induced Liver Injury.
Clin Gastroenterol Hepatol
September 2018
Department of Internal Medicine 2, Liver Centre Munich, University Hospital Munich (Klinikum der Universität München), Campus Großhadern, Ludwig-Maximilians-Universität Munich, Germany.
Background & Aims: Idiosyncratic drug-induced liver injury (iDILI) is one of the most challenging diagnoses in hepatology. It is frequently impossible to identify the agent that has caused iDILI in patients who take multiple medicines. We developed an in vitro method to identify drugs that cause liver injury in patients, based on drug toxicity to monocyte-derived hepatocyte-like (MH) cells from patient blood samples.
View Article and Find Full Text PDFPermeability analysis of neuroactive drugs through a dynamic microfluidic in vitro blood-brain barrier model.
Ann Biomed Eng
December 2014
Department of Bioengineering, University of Utah, SMBB 3100, 36 S. Wasatch Dr., Salt Lake City, UT, 84112, USA,
Article Synopsis
- - The study analyzes how well seven neuroactive drugs can pass through a dynamic microfluidic model of the blood-brain barrier (BBB) compared to traditional static models, using brain endothelial and glial cells.
- - Results show that dynamic models had significantly higher trans-endothelial electrical resistance (TEER) levels and lower permeability for the drugs, suggesting they more accurately mimic the in vivo environment than static models.
- - A strong correlation was found between the drugs' permeability values and their in vivo brain/plasma ratios, confirming that the dynamic microfluidic BBB model can effectively predict how drugs will clear from the brain.
Mitochondrial dysfunction induced by sertraline, an antidepressant agent.
Toxicol Sci
June 2012
Division of Genetic and Molecular Toxicology, National Center for Toxicological Research/U.S. FDA, Jefferson, Arkansas 72079, USA.
Sertraline, a selective serotonin reuptake inhibitor, has been used for the treatment of depression. Although it is generally considered safe, cases of sertraline-associated liver injury have been documented; however, the possible mechanism of sertraline-associated hepatotoxicity is entirely unknown. Here, we report that mitochondrial impairment may play an important role in liver injury induced by sertraline.
View Article and Find Full Text PDFSertraline-induced rhabdomyolysis in an elderly patient with dementia and comorbidities.
Ann Pharmacother
July 2009
Department of Experimental and Clinical Medicine, Faculty of Medicine and Surgery, University Magna Graecia of Catanzaro, Clinical Pharmacology and Pharmacovigilance Unit, Mater Domini University Hospital, Catanzaro, Italy.
Objective: To describe a case of sertraline-induced rhabdomyolysis in an elderly patient with dementia and comorbidities.
Case Summary: A 71-year-old woman visited a psychiatrist in September 2007 for her depressed mood. Her medical history included vascular dementia accompanied by depression, arterial hypertension, and heart failure, as well as cardiac pacemaker implantation several years earlier for severe bradyarrythmia.
Sertraline (L)-lactate: comprehensive profile.
Profiles Drug Subst Excip Relat Methodol
October 2012
Analytical Research and Development CT 06340 USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!